BBI Solutions Marks Solid Progress Since the Launch of ‘Game-Changing’ Technology

Leading immunoassay development and manufacturing specialist BBI Solutions has marked a successful first year since the launch of the landmark Morffi signal enhancement technology.

Leading immunoassay development and manufacturing specialist BBI Solutions has marked a successful first year since the launch of the landmark Morffi™ signal enhancement technology.

The disruptive technology has the potential to provide companies with a key competitive advantage in the marketplace because of the improved performance and faster results it offers.

The patent pending Morffi technology provides an up to ten-fold improvement in the limit of detection, enhanced assay sensitivity and may offer a faster time-to-result for situations where a quick diagnosis is critical to patient care.

The company has now deployed the Morffi technology against multiple different targets using monoclonal and polyclonal antibodies and utilising both sandwich and competitive assay formats. Evaluations have taken place across majority of diagnostic sectors where speed and improved sensitivity are crucial, showing some impressive results.

Leigh Thomas, Sales Director at BBI Solutions, said: “We’ve hit a number of key milestones since the launch of BBI’s ground-breaking Morffi signal enhancement technology and we are delighted that a number of our clients are exploring the significant benefits that it enables.

“Our expert team is focused on developing the highest-quality, most innovative solutions for immunoassays, and it is fantastic to see technology of this calibre coming out of our labs. We’re incredibly excited about the potential it can offer as it begins to transform the lateral flow landscape.”

Lateral flow immunoassays (LFIs) rely on specific interaction between the analyte of interest and an immobilised binding partner, such as an antibody or antigens improve performance and stability of conjugates, a blocking agent is bound to unoccupied sites on the reporter label, preventing non-specific binding.

However, the most commonly used conjugate blocker, BSA, can cross-react with human serum albumin-binding antibodies, bovine and other animal-origin targets, and traditionally exhibits lot-to-lot variability. Its relatively large size can also potentially lead to steric hindrance affecting the performance of the assay.

The proprietary Morffi technology overcomes these issues. Morffi technology utilises novel synthetic blocking agents that are significantly smaller in size than BSA. The size difference is believed to allow increased opportunity for successful interaction between the binding partner on the particle and the target analyte, resulting in enhancement of signal at the test line. The increased availability of the specific binding partner can also result in up to four times faster time to test result.

For more information about BBI Solutions or the Morffi technology, please visit http://bit.ly/Morffitechnology

MORE ON THIS TOPIC